ITCI - Intracellular Th - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ITCI is currently covered by 13 analysts with an average price target of $137.77. This is a potential upside of $5.9 (4.47%) from yesterday's end of day stock price of $131.87.

Intracellular Th's activity chart (see below) currently has 159 price targets and 174 ratings on display. The stock rating distribution of ITCI is 81.08% BUY and 18.92% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 93.88% with an average time for these price targets to be met of 480.05 days.

Highest price target for ITCI is $132, Lowest price target is $74, average price target is $108.17.

Most recent stock forecast was given by CHARLES DUNCAN from CANTOR FITZGERALD on 02-Apr-2025. First documented stock forecast 14-Apr-2015.

Currently out of the existing stock ratings of ITCI, 60 are a BUY (81.08%), 14 are a HOLD (18.92%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$132

$0.13 (0.10%)

$132

1 months 17 days ago
(02-Apr-2025)

28/30 (93.33%)

$0.13 (0.10%)

476

Buy

$132

$0.13 (0.10%)

$100

2 months 25 days ago
(24-Feb-2025)

10/11 (90.91%)

$3.46 (2.69%)

292

Hold

$100

2 months 28 days ago
(21-Feb-2025)

21/22 (95.45%)

$-27.19 (-21.38%)

170

Hold

$132

$0.13 (0.10%)

$113

3 months 18 days ago
(31-Jan-2025)

12/13 (92.31%)

$4.92 (3.87%)

738

Hold

$132

$0.13 (0.10%)

$108

3 months 27 days ago
(22-Jan-2025)

24/25 (96%)

$4.85 (3.81%)

233

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ITCI (Intracellular Th) average time for price targets to be met?

On average it took 480.05 days on average for the stock forecasts to be realized with a an average price target met ratio 93.88

Which analyst has the current highest performing score on ITCI (Intracellular Th) with a proven track record?

SUMANT KULKARNI

Which analyst has the most public recommendations on ITCI (Intracellular Th)?

Sumant Kulkarni works at CANACCORD and has 9 price targets and 9 ratings on ITCI

Which analyst is the currently most bullish on ITCI (Intracellular Th)?

David Amsellem with highest potential upside - $0.13

Which analyst is the currently most reserved on ITCI (Intracellular Th)?

Edward Nash with lowest potential downside - -$103.87

Intracellular Th in the News

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainablerevenue growth and achieve profit from...

Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI)

Enable social media cookies to share Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) By Mill Chart Last update: Apr 8, 2025 Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) is suited for growth investing. Investors...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?